Jazz Pharmaceuticals (FRA:J7Z) Retained Earnings: €983 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J7Z Jazz Pharmaceuticals PLC FRA:J7Z
74 GF Score
Price €210.20
GF Value €130.60
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Retained Earnings?

Jazz Pharmaceuticals FRA:J7Z -0.94% 74 Retained Earnings is €983 Mil as of Jun. 2026. GuruFocus rates FRA:J7Z with a GF Score™ of 74/100 and a GF Value™ of €130.60 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Jazz Pharmaceuticals's retained earnings for the quarter that ended in Jun. 2026 was €983 Mil.

Jazz Pharmaceuticals's quarterly retained earnings increased from Dec. 2025 (€552 Mil) to Mar. 2026 (€812 Mil) and increased from Mar. 2026 (€812 Mil) to Jun. 2026 (€983 Mil).

Jazz Pharmaceuticals's annual retained earnings increased from Dec. 2023 (€806 Mil) to Dec. 2024 (€1,077 Mil) but then declined from Dec. 2024 (€1,077 Mil) to Dec. 2025 (€552 Mil).


Jazz Pharmaceuticals  (FRA:J7Z) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Jazz Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Retained Earnings Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 734.75 692.51 805.73 1,076.62 551.83

Jazz Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.87 377.20 551.83 812.41 982.58
FRA:J7Z
74GF Score
Jazz Pharmaceuticals PLC FRA:J7Z
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €983 Mil mean?
Jazz Pharmaceuticals (FRA:J7Z) has a Retained Earnings of €983 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Retained Earnings too high?
Jazz Pharmaceuticals' current Retained Earnings is €983 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Retained Earnings compare to BBIO and ASND?
Jazz Pharmaceuticals' Retained Earnings of €983 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Retained Earnings is €983 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €130.60, compared to a current price of €210.20 — trading 60.9% above its estimated fair value. The current Retained Earnings is €983 Mil. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current Retained Earnings is €983 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €210.20 is trading 60.9% above its estimated GF Value™ of €130.60. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:J7Z:

  • Retained Earnings: €983 Mil
  • GF Value™: €130.60 vs. price of €210.20 (60.9% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score

Get the complete analysis for FRA:J7Z

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€210.20
Price
€130.60
GF Value